Account-based marketing best practices for 2026 for healthcare and life sciences

This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install account-based marketing has to reflect that reality from day one.

Best practices for account-based marketing have shifted. The 2022 playbook does not survive the current buyer environment. This is the update.

Best practice one: fewer accounts, sharper triggers. One enterprise close is worth six mid-market ones, and generic coverage is now negative signal.

Best practice two: publish pipeline created inside the named-account list weekly. If leadership does not see the number, the model quietly drifts.

The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Account-based marketing is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.

Best practice three: separate the sending infrastructure from the primary brand. Deliverability is a strategic asset.

Best practice four: name a single owner. Committees produce compromise; owners produce numbers.

Best practice five: pre-write kill criteria. A stated failure threshold is what prevents the sunk-cost trap.

Best practice six: run monthly retrospectives that are honest about what did not work. Account-based marketing improves faster on failure data than on success data.

Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing account-based marketing properly rather than half-heartedly across three vendors.